Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C32H40F3N5O5
CAS Number:
Molecular Weight:
631.69
UNSPSC Code:
12352209
NACRES:
NA.25
InChI key
GVPVVOSNDUAUKM-BPGOJFKZSA-N
SMILES string
N[C@@H](CCCNC(N)=N)C(O)=O.O=C(O)C[C@H]1CCC2=C1NC3=C2C=C(OCC4=CC=C(C5CCCC5)C(C(F)(F)F)=C4)C=C3
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (Warmed)
storage temp.
-10 to -25°C
Quality Level
Related Categories
Biochem/physiol Actions
Etrasimod arginine is an orally available, potent, and selective agonist of Sphingosine-1-Phosphate Receptors 1 (S1PR1). Also, it acts as a partial agonist of S1PR4,5. Etrasimod arginine induces reductions in lymphocyte counts in mice. It is acting as immunosuppressive agents.
Orally available, potent, and selective agonist of Sphingosine-1-Phosphate Receptors 1 (S1PR1)
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Hussien Al-Shamma et al.
The Journal of pharmacology and experimental therapeutics, 369(3), 311-317 (2019-03-16)
Lymphocyte trafficking out of secondary lymphoid organs is regulated by concentration gradient-dependent interactions between the membrane-derived lysophospholipid signaling molecule sphingosine 1-phosphate (S1P) and the G-protein-coupled receptor, S1P1 Etrasimod is a novel, next-generation, small-molecule, oral S1P receptor modulator in clinical development
Arianna Dal Buono et al.
Biomedicines, 10(7) (2022-07-28)
Inflammatory bowel diseases (IBDs) are chronic and disabling conditions that, uncontrolled, lead to irreversible bowel damage and associated comorbidities. Despite the new era of biological therapies, IBDs remain not curative. The treatment purpose is to induce endoscopic remission, reduce the
Matej Zore et al.
Frontiers in microbiology, 13, 926170-926170 (2022-06-24)
New classes of antibiotics are urgently needed in the fight against multidrug-resistant bacteria. Drug repurposing has emerged as an alternative approach to accelerate antimicrobial research and development. In this study, we screened a library of sphingosine-1-phosphate receptor (S1PR) modulators against
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service